ERBB2 and ductal breast carcinoma in situ: The results of these trials are currently not published, however the trial results by Estevés et al. assessing lapatinib in the pre-surgical setting reported significant inhibition of HER2 signalling and reduced tumor size following 4 weeks of treatment in HER2 positive DCIS patients [38].